Normosang (Human Hemin)

Human hemin supplies the body with heme, which exerts negative feedback on the enzyme aminolevulinic acid synthase, the first step in the heme biosynthetic pathway. By inhibiting this enzyme, the accumulation of upstream porphyrin precursors such as ALA and PBG is reduced, decreasing the neurotoxic effects that trigger acute porphyria attacks.

The specific dose of Normosang is determined by the treating physician based on the severity of the porphyria attack, patient weight, and clinical response. Dosing regimens are individualized and administered under specialist supervision, typically as an intravenous infusion over a defined period. Patients should follow the prescriber’s instructions precisely.

Safety data for human hemin in pregnancy and lactation are limited. The product should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case and discuss possible risks with the patient.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

The primary alternative to human hemin is the use of glucose loading, which can suppress ALA synthase but is less potent in severe attacks. Other heme preparations, such as heme arginate, have similar mechanisms but differ in formulation and regulatory status. Normosang offers a standardized injectable hemin product with established efficacy in acute episodes.

Normosang must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion must be discarded according to local regulations. Proper cold‑chain maintenance is essential to preserve stability.

Normosang is given as an intravenous infusion, typically through a peripheral or central line, under aseptic conditions. The infusion rate and duration are set by the prescribing physician, often over 30‑60 minutes, and the patient is monitored for infusion‑related reactions. Administration should occur in a healthcare setting equipped for emergency management.

Serious adverse events, though rare, include anaphylactic or severe hypersensitivity reactions, hemolysis, acute renal failure, and coagulopathy. Patients should be observed closely during and after infusion for signs of respiratory distress, sudden drop in blood pressure, dark urine, or abnormal bleeding, and immediate medical intervention should be initiated if these occur.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any excipients in the formulation. Caution is advised for individuals with severe hepatic or renal impairment, uncontrolled hypertension, or those receiving other porphyrinogenic drugs. Use should be avoided in patients without a confirmed diagnosis of an acute porphyria attack.